Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM. 2002. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging Infectious Diseases 8(8):796–801.

Fedson DS. 2004. Vaccination for pandemic influenza: A six point agenda for interpandemic years. Pediatric Infectious Disease Journal 23(Suppl 1):S74–S77.

Ferguson NM, Galvani AP, Bush RM. 2003. Ecological and immunological determinants of influenza evolution. Nature 422(6930):428–433.

Glezen WP. 2004. Control of influenza. Texas Heart Institute Journal 31(1):39–41.

Hoch D. 2004, May. Influenza pandemic preparedness: The European vaccine manufacturers’ perspective. ESWI Bulletin. [Online]. Available: http://www.eswi.org/ [accessed June 8, 2004].

Jin H, Zhou H, Lu B, Kemble G. 2004. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. Journal of Virology 78(2):995–998.

Kemble G, Greenberg H. 2003. Novel generations of influenza vaccines. Vaccine 21(16):1789–1795.

Lambert LC, Kim S. 2004, May. Pandemic preparedness: Developing a clinical trial research plan. ESWI Bulletin. [Online]. Available: http://www.eswi.org/ [accessed June 8, 2004].

McElhaney JE, Aoki FY. 2004, May. FluMist™: History and future. ESWI Bulletin. [Online]. Available: http://www.eswi.org/ [accessed June 8, 2004].

Palese P, García-Sastre A. 2002. Influenza vaccines: Present and future. Journal of Clinical Investigation 110(1):9–13.

Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG. 2004. Responsiveness to a pandemic alert: Use of reverse genetics for rapid development of influenza vaccines. Lancet 363(9415):1099–1103.


Barbera J, Macintyre A, Gostin L, Inglesby T, O’Toole T, DeAtley C, Tonat K, Layton M. 2001. Large-scale quarantine following biological terrorism in the United States: Scientific examination, logistic and legal limits, and possible consequences. Journal of the American Medical Association 286(21):2711–2717.

Epstein RA. 2003, Summer. Let the shoemaker stick to his last: A defense of the “old” public health. Perspectives in Biology and Medicine 46(Suppl 3):S138–S159.

Fedson, DS. 2004 (June 16–17). Reverse Genetics, Intellectual Property and Influenza Vaccination. Prepared for IOM Forum on Microbial Threats workshop: Pandemic Influenza: Assessing Capabilities for Prevention and Response, Washington, DC.

Gostin LO. 2004. International infectious disease law: Revision of the World Health Organization’s International Health Regulations. Journal of the American Medical Association 291(21):2623–2627.

Gostin LO, Bayer R, Fairchild AL. 2003. Ethical and legal challenges posed by Severe Acute Respiratory Syndrome: Implications for the control of severe infectious disease threats. Journal of the American Medical Association 290(24):3229–3237.

Gostin LO, Bloche MG. 2003. The politics of public health: A response to Epstein. Perspectives in Biology and Medicine 46(Suppl 3):S160–S175.

Mair JS, Mair M. 2003. Vaccine liability in the era of bioterrorism. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 1(3):169–184.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement